Matched unrelated umbilical cord blood transplantation for a patient with chemotherapy resistant Wilms tumor.
We report a patient with chemotherapy refractory Wilms tumor who underwent an unrelated donor cord blood transplant for chemotherapy refractory disease. The preparative regimen consisted of busulfan, melphalan, and anti-thymocyte globulin, and was well tolerated. This patient did not experience significant toxicity related to the chemotherapy regimen and did not develop any graft versus host disease from his HLA (A, B, DR) 6/6 matched cord blood transplant. Follow-up CT scans 2 years post-transplant have shown no evidence of disease progression, with only a few pulmonary nodules remaining, which are unchanged in size from his pre-transplant CT scan. It is possible that high-dose chemotherapy and stem cell transplantation can be curative in patients with tumors that are non-responsive to conventional chemotherapy.
Lucas
Kenneth G
KG
Stem Cell Transplantation Program, Division of Hematology/Oncology, Department of Pediatrics, Penn State Children's Hospital, Hershey, Pennsylvania 17033, USA. klucas@psu.edu
Shapiro
Terry
T
Freiberg
Andrew
A
Frauenhoffer
Elizabeth
E
D002675:Child, Preschool; D036101:Cord Blood Stem Cell Transplantation; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D014184:Transplantation, Homologous; D009396:Wilms Tumor / Q000628:therapy*